Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 2/20 | 0.38 |
| ▸ | ALB | P02768 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PTGES | O14684 | 4/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4352165 | 0.82 | ERN1 (0.36) | ERN1ALDH1A1POLB | |
| SCHEMBL4341634 | 0.82 | ALDH1A1 (0.40) | ALDH1A1HPGDL3MBTL1PTGESPOLB | |
| SCHEMBL4351731 | 0.78 | PTGES (0.36) | ERN1ALDH1A1L3MBTL1PTGES | |
| SCHEMBL4347354 | 0.77 | KMT2A (0.46) | ALBALDH1A1POLBGAATP53 | |
| SCHEMBL4351134 | 0.75 | ERN1 (0.36) | ERN1ALDH1A1HPGDL3MBTL1PTGES | |
| SCHEMBL4354007 | 0.75 | NPC1 (0.46) | ALDH1A1HPGDGAAHTT | |
| SCHEMBL4350070 | 0.74 | NAAA (0.40) | ALDH1A1HPGDHTT | |
| SCHEMBL4358609 | 0.74 | POLB (0.40) | ALBALDH1A1HPGDPOLBTP53 | |
| SCHEMBL4341747 | 0.73 | TSHR (0.45) | ALDH1A1GAAHTTNPSR1 | |
| SCHEMBL4344053 | 0.72 | GAA (0.41) | ALDH1A1GAAHTTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110065760-A1 | COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF | JERINI AG (DE) | 2011-03-17 | — | — | US | claimed |
| EP-2100876-A2 | New compounds for the inhibition of rotamases and use thereof | Jerini AG (DE) | 2009-09-16 | — | — | EP | claimed |
| US-20070054904-A1 | Phenol derivatives and their use as rotamase inhibitors | JERINI AG (DE) | 2007-03-08 | — | — | US | claimed |
| EP-2100876-A2 | New compounds for the inhibition of rotamases and use thereof | Jerini AG (DE) | 2009-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065760-A1 | COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF | NR1I3, NR1D1, NR1D2 | ERN1 1860/4885ALB 4701/4885ALDH1A1 2565/4885 |
| US-20070054904-A1 | Phenol derivatives and their use as rotamase inhibitors | NR1I3, NR1D1, NR1D2 | ERN1 1686/4885ALB 4431/4885ALDH1A1 2767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.